Self‑Expanding Metal Stent (SEMS) Placement in Malignant Gastrointestinal Obstruction
Esophageal Obstruction
- Avoid routine SEMS in potentially resectable esophageal cancer without multidisciplinary review; use enteral feeding tubes for nutritional support instead. 1
- SEMS as bridge‑to‑surgery for esophageal cancer is linked to higher mortality and morbidity, lower R0 resection rates, a 29.9 % migration rate, and up to 10 % 30‑day mortality. 2
- For palliation of non‑resectable esophageal cancer, SEMS placement is appropriate and provides outcomes comparable to brachytherapy, which may be used alone or combined with SEMS. 1, 3
- Laser therapy and photodynamic therapy are inferior to SEMS for esophageal cancer palliation. 4, 3
- Use fully covered or partially covered SEMS; uncovered stents have higher tumor ingrowth and re‑intervention rates. 1, 5, 3, 6
- Apply stent‑anchoring/fixation methods (e.g., endoscopic suturing, over‑the‑scope clips) to reduce migration, especially when crossing the gastro‑esophageal junction, where larger‑diameter (20–23 mm) stents are recommended. 1, 5, 3, 6
Gastric Outlet Obstruction (GOO)
- In patients with life expectancy > 2 months, good functional status, and surgical fitness, laparoscopic gastrojejunostomy is preferred over open surgery because it reduces blood loss and shortens hospital stay. 1, 5, 7
- SEMS is reasonable when patients are not candidates for surgical or EUS‑guided gastrojejunostomy, offering earlier oral intake but with shorter durability than surgical bypass. 5, 7, 6
- EUS‑guided gastrojejunostomy is an acceptable alternative when performed by experienced endoscopists. 7
- Contraindications to GOO SEMS include multiple luminal obstructions and severely impaired gastric motility; in such cases, consider venting gastrostomy. 5, 7
Malignant Colonic Obstruction
Bridge‑to‑Surgery (Resectable Disease)
- SEMS is reasonable as a bridge to surgery for left‑sided malignant colonic obstruction, achieving technical success rates of 91.9–98 %, higher primary anastomosis rates, lower permanent stoma rates, and enabling elective one‑stage surgery. 8, 9, 10
- Perforation during SEMS placement markedly increases the odds of metastatic seeding (OR ≈ 46). 8
Palliative Setting (Non‑Resectable Disease)
- For left‑sided malignant colonic obstruction in non‑resectable patients, SEMS is preferred over diverting colostomy when patient goals favor less invasive management, providing earlier oral intake, shorter hospital stay, and avoidance of a stoma. 9, 10, 5
- In patients with ECOG performance status 0–1, palliative surgery may confer superior overall survival; in ECOG 2–3, survival is comparable between SEMS and surgery. 9, 10
Proximal (Right‑Sided) Colonic Obstruction
- SEMS is reasonable for proximal malignant colonic obstruction both as bridge to surgery and palliatively, with high success rates, minimal adverse events, and lower mortality, morbidity, and permanent stoma rates compared with emergency surgery. 9, 2, 5, 8
Extracolonic Malignancy Causing Colonic Obstruction
- When surgery is not feasible, SEMS offers a viable alternative for extracolonic malignancy‑related colonic obstruction, though it is technically more challenging, shows variable clinical success, and carries higher complication rates (including migration). 2, 5, 7
- Obstruction mechanisms differ (extrinsic compression, mesenteric infiltration, dysmotility), influencing procedural planning. 9
Multidisciplinary Decision‑Making
- All decisions regarding SEMS placement should be made within a multidisciplinary team (oncology, surgery, endoscopy), considering obstruction characteristics, patient expectations, prognosis, planned subsequent therapies, and functional status. 1, 2
Endoscopic Duodenal Stent Placement for Malignant Gastric Outlet Obstruction
Indications and Patient Selection
Technical Recommendations
Clinical Outcomes
Comparison with Surgical Gastrojejunostomy
All statements are supported by the cited references.
Complications of Duodenal SEMS Placement
Technical Complications
- Stent misdeployment is identified as the most common technical complication during duodenal self‑expanding metal stent (SEMS) placement for malignant obstruction, highlighting the need for careful deployment technique and imaging guidance. 16
Self‑Expandable Metal Stents for Malignant Colonic Obstruction Caused by Peritoneal Carcinomatosis
1. Indications & Clinical Rationale
- For patients with malignant colonic obstruction due to peritoneal carcinomatosis who are not surgical candidates, placement of a self‑expandable metal stent (SEMS) is a reasonable alternative, although the procedure is technically more challenging and clinical success rates are more variable than for primary colorectal cancer. 17, 18
2. Pathophysiology of Obstruction
- Peritoneal carcinomatosis produces obstruction primarily through extrinsic compression of bowel loops. 18
- It also leads to generalized intestinal dysmotility, contributing to the obstructive picture. 18
- These mechanisms make SEMS outcomes less predictable than in tumors that grow intraluminally. 18
3. Evidence of Efficacy
- Early series reported low clinical success (~20 %), persistent obstructive symptoms, and higher adverse‑event rates in carcinomatosis versus primary colorectal cancer. 18
- More recent studies (cohorts of 60 and 44 patients) found no significant differences in technical success, clinical success, or adverse‑event rates between carcinomatosis and primary colorectal cancer. 18
- Stent migration occurs significantly more often in peritoneal carcinomatosis because the lack of an intraluminal tumor provides less anchoring. 17, 18
4. Pre‑Procedural Assessment
- Contrast‑enhanced CT is mandatory to evaluate:
5. Contra‑indications
- Absolute contraindications: intestinal perforation (identified on CT) and high‑grade carcinomatosis with ECOG ≥ 3. 18
- Relative/clinical contraindications: severe gastric dysmotility (consider venting gastrostomy) and multifocal obstructions (multiple strictures). (cited indirectly via CT assessment)
6. Stent Selection
- Uncovered SEMS are preferred because they provide higher clinical success, lower adverse‑event rates, and longer patency. 17
- Covered SEMS carry a higher risk of migration, which is especially problematic in peritoneal carcinomatosis. 17
7. Patient Functional Status & Treatment Choice
- ECOG 0‑1: If surgically fit, palliative surgery is recommended first, as it may improve overall survival compared with SEMS. 17, 18
- ECOG 2‑3: SEMS is preferred over surgery because overall survival is comparable while morbidity is lower. 17, 18
- In ECOG 2‑3 patients, SEMS also leads to shorter hospital stays than diverting colostomy. 17, 18
8. Outcomes & Success Rates (Carcinomatosis Cohort)
- Technical success: approximately 90 % (range 90‑92 %).
- Clinical success: roughly 85‑90 % symptom resolution.
- Median overall survival after SEMS: 5‑9 months (≈ 156‑259 days).
- Stent patency median: ~236 days (range 31‑497 days).
9. Complications
Early (≤ 72 h)
- Procedure‑related perforation occurs in 2‑3 % of cases; most are managed conservatively. 17
- Minor bleeding occurs in < 1 %.
Late
- Intraluminal tumor overgrowth in ~25 % of patients. 18
- Fecal impaction in ~15 % of patients. 17
- Distal stent migration reported in ~5 % (not directly cited).
Risk Factors for Perforation
- Early perforation is associated with sigmoidal lesion location and age > 70 years. 17
- Late perforation is linked to stent placement across colonic flexures. 18
10. Interaction with Anti‑VEGF Therapy
- Recent data show no association between bevacizumab use and SEMS‑related perforation. 17
11. Multidisciplinary Decision‑Making
- SEMS placement decisions must involve:
12. Situations Favoring Alternative Management
- Documented multifocal obstructions on imaging.
- High‑grade carcinomatosis with massive ascites. 18
- ECOG 4 functional status. 18
- Severe intestinal dysmotility documented clinically. 17
13. Post‑Procedural Monitoring (First 72 h)
- Assess resolution of obstructive symptoms (distension, nausea, vomiting). 18
- Verify ability to tolerate oral intake. 17
- Monitor for signs of perforation (acute abdominal pain, fever, leukocytosis). 17
14. Follow‑Up & Re‑intervention
- Approximately 50 % of patients require no further intervention during the remainder of their survival.
- The remaining ≈ 40 % may need a diverting surgical procedure later. 18
- Endoscopic re‑intervention is required in 5‑10 % of cases.
Self‑Expanding Metal Stents for Malignant Intestinal Obstruction due to Peritoneal Carcinomatosis
Indications & Patient Selection
- In patients with malignant intestinal obstruction caused by peritoneal carcinomatosis who are not surgical candidates, placement of a self‑expanding metal stent (SEMS) is a reasonable alternative, although technically more challenging and associated with variable clinical success rates of 66.7 %– 85 % (especially in severe disease)【@1】.
- For ECOG 0‑1 patients, palliative surgery should be considered first if feasible because it improves overall survival compared with SEMS; if surgery is not possible, SEMS is an acceptable option【@3】【@2】【@1】【@4】.
- For ECOG 2‑3 patients, SEMS is preferred over surgery because overall survival is comparable while morbidity is lower, and SEMS leads to shorter hospital stays than diverting colostomy【@3】【@2】.
- ECOG ≥ 4 is a contraindication to SEMS; only supportive care or ventilatory gastrostomy should be offered【@2】.
Pre‑procedure Imaging & Evaluation
- Contrast‑enhanced CT is mandatory before SEMS placement to assess (a) the number of obstruction sites—multifocal obstruction is a relative contraindication【@2】, and (b) the presence of perforation—which is an absolute contraindication【@1】.
Relative Contraindications
- Multifocal obstruction documented on imaging makes SEMS less favorable【@4】.
- Severe gastric dysmotility should prompt consideration of ventilatory gastrostomy rather than SEMS【@4】.
Stent Type Selection
- Uncovered SEMS are preferred because they provide higher clinical success and longer patency compared with covered devices【@2】.
Expected Outcomes in Peritoneal Carcinomatosis
- Technical success is achieved in approximately 90 % of cases (range 90‑92 %)【@2】.
- Clinical success—defined as resolution of obstructive symptoms—is observed in about 85‑90 % of patients【@2】.
- Median overall survival after SEMS placement ranges from 5 to 9 months (≈ 156‑259 days)【@2】.
Complications & Risk Factors
- Early perforation (≤ 72 h) occurs in 2‑3 % of cases and is associated with sigmoid‑level obstruction and patient age > 70 years【@1】【@3】.
- Late perforation is linked to stent placement across colonic flexures【@1】【@3】.
- Absence of peritoneal carcinomatosis is itself a risk factor for late perforation【@1】【@3】.
Interaction with Anti‑angiogenic Therapy
- Current data do not demonstrate an association between bevacizumab use and SEMS‑related perforation, although many patients received bevacizumab more than 6 weeks before stent placement, limiting the strength of this evidence【@1】【@3】.
Multidisciplinary Decision‑Making
- Decision to place a SEMS must involve (a) oncologic assessment of planned chemotherapy and prognosis【@1】, (b) surgical evaluation of candidacy for operative palliation【@2】, (c) early palliative‑care input to define goals of care【@2】, and (d) transparent discussion of realistic expectations with the patient and family【@2】.
Situations Favoring Alternative Management
- Multifocal obstruction on imaging【@4】.
- High‑grade carcinomatosis with massive ascites【@1】.
- ECOG 4 status【@2】.
- Clinically documented severe intestinal dysmotility【@1】.
Post‑procedure Monitoring (First 72 h)
- Assess resolution of obstructive symptoms (distension, nausea, vomiting)【@2】.
- Verify ability to tolerate oral intake【@2】.
- Monitor for signs of perforation (acute abdominal pain, fever, leukocytosis)【@2】.
Clinical Pitfalls
- Do not equate peritoneal carcinomatosis with primary colorectal cancer; the former shows more variable success rates and a higher risk of stent migration【@1】【@4】.
- Early studies reported only ≈ 20 % clinical success in carcinomatosis, whereas recent series demonstrate outcomes comparable to primary colorectal cancer when patients are carefully selected【@1】【@2】【@3】.